The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1389
In Brief: Warning about Drospirenone in Oral Contraceptives
Download PDF:   US English
 Select a term to see related articles  Beyaz   Contraceptives   Drospirenone   Levonorgestrel   Oral contraceptives   Safyral   Venous thromboembolism   Yasmin   Yaz 

The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone (Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of thromboembolism than CHCs containing other progestins.1

The new warning was based partly on an unpublished, FDA-funded, retrospective study that found a 1.7-times higher risk of venous thromboembolism among US women who used a CHC that contained drospirenone than among women whose CHC contained levonorgestrel, norgestimate or norethindrone as the progestin component.2 As with all retrospective studies, unknowable confounding factors, such as why doctors prescribed one progestin over the other, could have distorted the results.

All CHCs increase the risk of venous thromboembolism; whether the progestin component affects the risk has been controversial. The Medical Letter and several other reviews and consensus statements have found no convincing evidence of an increased risk with drospirenone.3-5

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.